Scientific Literatures Archive

April 3, 2023

Effects of the p38-Alpha Kinase Inhibitor Neflamapimod on the Basal Forebrain in Patients, Assessed by Structural MRI

December 2, 2022

LP102 Effects of the p38α kinase inhibitor neflamapimod on the basal forebrain, as assessed by structural MRI, in Alzheimer’s Disease

15th CTAD LP102 Poster Alam et al December 2nd 2022

September 21, 2022

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Peer-reviewed publication in the journal Nature Communications

November 10, 2021

OC5 – Effects of the oral p38α kinase inhibitor neflamapimod on motor function (gait) in patients with mild-to-moderate dementia with Lewy bodies (DLB)

14th CTAD Oral Communication OC5 Alam et al November 10th 2021

May 27, 2021

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Prins et al: Alzheimer’s Research & Therapy – Published: 27 May 2021

December 4, 2020

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level

PLOSOne Dec 2020:

September 8, 2020

Functions of p38 MAP Kinases in the Central Nervous System

Journal – Frontiers in Molecular Neuroscience. 13:570586, 2020.

July 31, 2020

P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease

International Journal of Molecular Sciences. 2020; 21(15): 5485.

May 31, 2020

Neuronal deficiency of p38α‐MAPK ameliorates symptoms and pathology of APP or Tau‐transgenic Alzheimer’s mouse models

Journal – The FASEB Journal. 34(7):9628-9649, 2020.

May 29, 2018

Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers

Frontiers in Aging Neuroscience. Volume 10, Article 155, 2018.

December 6, 2017

Forecasting the Prevalence of Preclinical and Clinical Alzheimer’s Disease in the United States

Alzheimer’s & Dementia. Volume 14, Issue 2, 2018.

March 31, 2017

Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production

Scientific Reports. Volume 7, No. 45306, 2017.

March 30, 2017

Aged Dominant Negative p38α MAPK Mice are Resistant to Age-Dependent Decline in Adult-Neurogenesis and Context Discrimination Fear Conditioning

Behavioural Brain Research. 322, 2017.

January 31, 2017

Glucose Deﬁcit Triggers Tau Pathology and Synaptic Dysfunction in a Tauopathy Mouse Model

Translational Psychiatry. 1:9, 2017.

December 15, 2016

Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology

Alzheimer’s Research & Therapy. 8:54, 2016.

November 1, 2016

Targeting Neuronal MAPK14/p38α Activity to Modulate Autophagy in the Alzheimer Disease Brain

Autophagy. Volume 12, No. 12, 2016

December 9, 2015

Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1

Journal of Biological Chemistry. Volume 291, No. 5, 2016.

September 8, 2015

Synapse-Specific IL-1 Receptor Subunit Reconfiguration Augments Vulnerability to IL 1β in the Aged Hippocampus

Proceedings of the National Academy of Sciences of the United States of America. 2015.

December 11, 2012

p38α Mitogen-Activated Protein Kinase Depletion and Repression of Signal Transduction to Translation Machinery by miR-124 and -128 in Neurons

Molecular and Cellular Biology. Volume 33, No. 1, 2012.